Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
just topped up again! 5K @ 61.3.
average up to circa 40p
I didnt see that! good spot. Building credible holders here
No idea, its closing slowly. Tbh even if the share price starts going up and the spread remains at 20-30% we will see good days here.
I just have a hunch that with all the pharma working going on with covid19 and there's evidence of DMTR being involved in the process now, its only a matter of time. The beauty of this stock, its tech to help any drug development. COVID19 will build the hype for this and this stock will be hear long after covid19 has dissappeared and testing covid19 stocks begin to fall in 6 months after the testing market is saturated by a few key players
id be happy to maintain above 3.10 today if possible and close the spread
3.50 Open 24% up
right-click on your screen, click inspect. Then go to application in the top right, click clear site data. Log back in
Its because LSE cant handle the amount of traffic and there's alot of cached data
100% this is awesome news! Glad im in here.
True! Im taking the fact that the big buys during this type of spread show something positive might happen. Why load up 50k+ if you don't think that it will gap up and make a profit.
Just wait guys!
The same reason pretty much any stock. Validation and approval from the big dogs in the industry. Just because AZ took on the partnership last year doesn't mean its fully validated. Like any tech, you need to get social proofing from vendors. if they are using this for covid19 drugs there's your social proof. If they aren't then we wait for more news on what compositions they are using this for within AZ. If AZ delivers a drug ans there is a case study stating DMTR software and hardware increased production time ot market then this is the goal of any tech company.
pretty simple
If anyone wants any further knowledge.DeviceX alone is a game-changer in the pharma industry, as this dramatically increases the r&d session to formulate the structure of new molecular solutions.
Previous they would create molecules and then evaluate the composition using processes after delivery. DeviceX is a realtime data feed to enable chemists to review formula composition in real-time.
This isn't even to mention the technology behind it. The hardware alone is a frickin' game changer.
Im new to investing and have invested in some pharma stock off a lot of research and trends. But this stock i about tech and data which i do in my day to day job. Finally found the first stock that I can get fully invested in with my knowledge of technology and Ai
There's some serious potential for this! Big data in science is not mature yet, but jeez man big data Ai in any field in worth billions and saves billions.
You only have to research IBM Watson and how they chewed up the market to deliver that and the benefits to business, to see the expectations with this stock.
Good luck all!
Everyone needs to chill. This will have its day The only data-driven support service for the most required sector for the next 24 months easily
There isnt any time frames! If AZ benefit from the software then this is a bagger for sure. Lets be conservative here. If AZ benefits from the software it would just be an initial commercial success, they will scale it out across their various functions. If the partnership with AZ looks positive then id says 6 months before it reaches anywhere near 30p.
And in all honesty in Ai world, the big players make an offer small companies like DMTR can refuse. I expect an exit from this in 12 months after the point the partnership with AZ is showing signs of significant benefits.
Whats is happening. Everyone actually sounds sensible on this thread haha!
Wait until this starts to scale and the board is flooded with nutters. 10p target is also what I had in sight. I think this is easily achievable if AstraZ is benefitting from the tech
True but usually tech companies buy tech companies. Its very rare you see a pharma company buying tech and hardware. The cost to maintaining this after purchase is a nightmare. Companies focus on what they do best and microsoft will sniff this way before pharmas do. If ASK bought this, then all other pharmas probably wouldn't be able to use it, so exit value for DMTR would only be for the use of one company. ASK might by a share, but they would never want to take the lead.
If microsoft came knocking DMTR could demand a higher exit as Microsoft could role this out at a quicker rate to more pharmas
Whether this is used for COVID19 or after covid19 this is a must-watch. I run a tech start-up in identity verification with biometric data. That totally changed the way the finance industry verified AML and KYC checks through data lakes and advanced ML and anomaly recognition. That market alone is going to be worth $65 billion by 2024 and there are only a few front runners that stand out because they are trusted.
History in tech shows that data is vital for early confirmation of anything whether fraud, sales and in this case molecular structures. I have done vast research on this stock and cannot see anyone who is anywhere near or even thinking about what this company can achieve.
I would reckon that some big players might be using this system right not to establish molecular structures for covid19 drugs. If not then this is 100% something that will be used to save the big pharma companies a ton of r&d and remove wastage in the lab.
I would probably see someone like Microsoft making a move for a company like this as they are leading the way in Ai driven services. They bought open Ai to build systems to use for agriculture and health care already. This kind of system deepmatter has developed is an ideal candidate to add to a big tech companies service portfolio.
Watch this space guys!
I agree. I was hoping we could see a rise to 5p over the week based on the initial news. Wasnt expecting a day rise of 140%